Medpace Holdings Inc (MEDP)vsNovartis AG ADR (NVS)
MEDP
Medpace Holdings Inc
$587.52
+0.75%
HEALTHCARE · Cap: $16.49B
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1938% more annual revenue ($56.69B vs $2.78B). NVS leads profitability with a 22.5% profit margin vs 17.7%. MEDP appears more attractively valued with a PEG of 2.81. MEDP earns a higher WallStSmart Score of 68/100 (B-).
MEDP
Strong Buy68
out of 100
Grade: B-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-39.2%
Fair Value
$304.57
Current Price
$587.52
$282.95 premium
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 113 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.8%
17.2% revenue growth
Earnings expanding 37.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 37.8x book value
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 20.8%. Revenue growth of 17.2% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, Altman Z-Score, PEG Ratio.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
MEDP profiles as a growth stock while NVS is a value play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.15 — expect wider price swings.
MEDP is growing revenue faster at 17.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (68/100 vs 51/100), backed by strong 17.7% margins and 17.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?